The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
The programme gives farmers and veterinary surgeons access to new resources, enabling a coordinated and consistent approach to farmer training in the responsible use of antibiotics.
The development of the AMBP Programme has been led by NOAH in partnership with a group of stakeholders from across the industry including farmers, vets, the Responsible Use of Medicines in Agriculture Alliance (RUMA), the Veterinary Medicines Directorate (VMD), the British Retail Consortium (BRC) and leading academics, to create a training programme for all those working in the sheep, dairy, beef and pig sectors.
NOAH says the programme will raise awareness, knowledge and understanding of antimicrobial resistance (AMR) and help drive best practice in a consistent manner across UK farms when it comes to using antibiotics.
Training modules are available for farmers to access via the NOAH website or directly through an online Lantra eLearning platform.
In addition to the direct farmer offering, veterinary surgeons will also be to access resource materials, enabling them to deliver training to their clients. This veterinary resource centre will follow soon.
NOAH Chair, Gaynor Hillier, said: "We know that there is a real demand for this type of accessible training and we’re delighted to be able to lead the way in making it available.
"This new collaborative, cross-sector strategy on training will support both farmers and vets, demonstrating that our farmers have the skills to use antibiotics responsibly, providing reassurance to consumers and policy makers. NOAH is happy to be building on existing antibiotic stewardship achievements within the farming sector as ensuring best practice is vital to safeguard the future efficacy of antibiotics for us all.”
Biosecurity Minister Lord Gardiner said:
"The UK is at the forefront of global efforts to tackle antibiotic resistance. Recent statistics show there has been a 27 per cent drop in use of antibiotics in food-producing animals in the UK since 2014 - meeting a government commitment two years early.
"Our farmers and vets must be commended for driving down antibiotic use in livestock to this all-time low - setting an excellent example for others around the world to follow. But it is vital we continue making progress.
"We welcome this new responsible use of antibiotics farmer training programme, which will support the animal medicines industry to take another positive step towards tackling resistance, safeguarding antibiotics for future generations."
Photo: Lord Trees introduced the launch event and outlined his support for the AMBP programme.
Birds at two Bernard Matthews breeder sites in Suffolk and Norfolk have tested positive for avian influenza, though not the highly pathogenic H5 or H7 types.
A movement restriction has been put in place by DEFRA, but a cull has not so far been required. The BBC has the full story at: http://news.bbc.co.uk/1/hi/england/7912529.stm
A short survey, which has been emailed to BVA members this week, asks respondents to confirm which Official Controls Qualifications (OCQ(V)s) they currently hold or previously held.
They are also asked to give reasons if they have chosen to drop a particular qualification without revalidating it.
The BVA says members have raised concerns via Council about the OV training and revalidation process, citing time, cost, a lack of relevance and duplication of learning across different modules as reasons for choosing not to renew their qualifications.
The BVA plans to take the data and insights captured in the survey to the Animal and Plant Health Agency (APHA) and make recommendations for how the system can be made more user-friendly and fit for purpose.
John Fishwick, BVA President, said: "Official Veterinarians have a critical role to play in upholding high standards of health and welfare across the supply chain, certifying products for export and safeguarding against disease and food fraud. We are already aware that this area is facing significant challenges as Brexit is likely to drive up demand for product certification.
"It is particularly worrying to hear that members are finding the system both frustrating and resource-intensive. Losing skilled professionals now at a time when they are needed most would be a real waste of specialist knowledge and could leave gaps in the UK’s provision for responding to disease outbreaks and meeting export certification needs post-Brexit.
"We understand and support the need to keep veterinary skills up to date, but the process for demonstrating this must be straightforward and proportionate. BVA will ensure that all insights offered by respondents are raised with APHA with the aim of getting the system right for OVs working in the UK both now and in the future."
BVA members can access the survey at https://www.surveymonkey.co.uk/r/7Y2Y3RR. The deadline for responding is 29 June 2018.
During the webinar, panel contributors Fiona Lovatt (past president of Sheep Veterinary Society), Jenny Hull (Black Sheep Farm Health, Northumberland), Lesley Stubbings OBE (lead member of SCOPS and independent sheep consultant), and Phillippa Page, (independent sheep vet consultant) will discuss:
The first 250 delegates to sign up will receive a copy of the In Practice supplement as well as a Zolvix notebook and pen.
https://app.livestorm.co/elanco-animal-health/flock-health-in-practice-webinar
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
In 2014 ioLight co-founders, Oxford physicists Andrew Monk and Richard Williams, filed a patent application for a pocket-sized digital microscope with a performance that compares with expensive laboratory microscopes. They asked Cambridge Industrial Design to realise the product, briefing them that the device would need to deliver images with one micron resolution (required to view human or animal cells) onto a smartphone or tablet, be pocket-sized, easy to use, and economical to build in medium to high volumes.
One of the biggest challenges was in making the unit pocket-sized, which meant it had to be foldable, something which could have led to a loss in the rigidity needed to achieve high resolution images. This challenge was overcome with the use of a single hinge which the company says makes the ioLight both portable and robust.
Alex Jones, Managing director of Cambridge Industrial Design said: "We recognised immediately this was a great idea but the design brief was certainly a challenge. Fortunately, challenges can sometimes bring out the best in designers. The final design is a real success both aesthetically and ergonomically, and this award is a fantastic acknowledgement for the design process and the final product that we have created together with ioLight."
ioLight is also celebrating another success: closing its second round of equity funding after raising £320k from 335 investors on the Crowdcube platform (128% of the initial target).
The company says the new funding will allow it to promote the microscope to a wide range of target markets including veterinary surgeons, education, laboratory and field research, museums and public engagement as well as to international markets.
Andrew Monk, ioLight’s co-founder said: "The product is so simple to use that it is the ideal communication tool for explaining science to the public, students and customers. The microscope lets everyone see the same image so the discussion is about the picture not the tools. It’s a perfect fit for government public engagement campaigns, which are well funded at the moment. We are absolutely delighted that this funding provides us with the opportunity for both product development and to reach out and make microscopy available to so many more people."
Pfizer VPS has launched a 'Pre-Sale Scab Treatment Certificate' so that sheep treated for sheep scab and protected against re-infestation beyond their autumn sale date can be formally certified as such.
A choice of two moxidectin-based treatments are eligible for use, one with 28 days and the other 60 days licensed persistency against the scab mite.
Pfizer VPS vet David Bartram explained that following treatment, the sale date must fall within the persistency window: "The idea is that farmers present their certificate at markets on sale day, then auctioneers announce the scab-protected status during their sales patter. Whether this adds to the sale price will be interesting to find out, but it's sure to be seen as a valuable attribute by buyers who won't need to treat for scab when they arrive home."
Details of the certification process are available from SQPs at animal medicine suppliers. The two eligible treatments are CYDECTIN 1% LA and CYDECTIN 2% LA for sheep.
The EU Commission has approved the marketing authorisation variation of Boehringer Ingelheim's PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the European Union.
Boehringer says it will market this unique vaccine concept under the name FLEXcombo. The company highlights that protection against two of the most prominent and costly pig diseases, Porcine Circovirus Disease (PCVD) and Enzootic Pneumonia, can now be achieved with a single injection instead of up to four injections. More than 70% of European pigs are currently vaccinated against both these diseases.
According to the company, the combined use of Ingelvac CircoFLEX and Ingelvac MycoFLEX is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind.
Dr. Joachim Hasenmaier, global head of Animal Health within BI said: "We are very proud that we can now also supply EU veterinarians and farmers with this latest innovation that will help tremendously in reducing the number of injections to pigs, supporting the wellbeing of the animals and the farm economics by saving a substantial amount of labour."
Vetoquinol is advising vets and farmers to be on the lookout following the discovery of counterfeit Marbocyl on two farms in Northern Ireland.
The counterfeit product contains an unapproved source of Marbofloxacin in an untested formulation which presents an unknown risk to animal and human health if used.
Vetoquinol has informed the national authorities about this situation. It is illegal either to sell or supply the product or to knowingly buy and/or use it.
The withdrawal period of this counterfeit product is unknown. Should the product be used it could be detected in milk or after slaughter. Vetoquinol advises the veterinary community to be aware of the risk, to carefully check the product packaging before use and to continue to source the product from reputable suppliers.
Vetoquinol urges vets and farmers to take the following actions if you find this product on farm or are approached to purchase it:
Vetoquinol says vets can rest assured that it will do all that is necessary to remove this product from the market.
If you need further information or advice, do not hesitate to contact Vetoquinol on 0800 1698197.
The industry-led Cattle Health and Welfare Group of Great Britain (CHAWG) has published a review which identifies a practical approach to gathering antibiotic usage data on UK cattle farms.
The review outcomes, announced today at a joint conference held by the Responsible Use of Medicines in Agriculture Alliance (RUMA) and the Veterinary Medicines Directorate (VMD), highlight the significant benefits better data could deliver, such as improving the way antibiotics are administered strategically to tackle disease.
But CHAWG’s chair Tim Brigstocke says it’s also important that the industry is able to accurately report usage levels because of the rising levels of antibiotic-resistant bacteria which threaten human health.
"We found that while data is already stored at every vet practice and in every farm medicine book, it currently exists in many different forms. It’s also not collected or collated, and is further complicated by multi-species approvals for many of the antibiotics.
"This means we can’t always be sure in which type of animal a medicine has been used. For example, out of 420 tonnes of animal-authorised antibiotic active substance sold in the UK in 2013, only 14 tonnes was authorised solely for use in cattle. However, 63 tonnes was authorised for multi-species use in food producing animals and within the 217 products included in this, 201 are authorised for use in cattle."
Tim says that with the support of the VMD, which requested the review and will now act as secretariat, CHAWG will set up a working group to implement the report’s recommendations.
The starting point is likely to be the survey of vets carried out by the British Cattle Veterinary Association (BCVA), which formed part of the review. This suggested vets could be using as many as 15 different software programmes to log data, so CHAWG will be working with the BCVA and individual practices to look at how standard sets of data can be anonymised and exported.
"Then we will almost certainly look at how cattle farmers can be supported in migrating records from the physical ‘medicine book’ on the farm, into a spreadsheet or existing cattle management software for anonymous aggregation on a national level.
"There are undoubtedly areas where we can improve the effectiveness of how we use these powerful medicines to improve welfare. But the antibiotic resistance debate is an emotive one and we must also demonstrate accountability to ensure the preservation of antibiotics for future use in humans and animals; any future curbs on usage should be proportionate and informed, and not compromise animal wellbeing."
Mandatory reporting in Europe could be just over the horizon and the European Medicines Agency has focused in the past year on developing a method for data collection on the usage of antibiotics in the EU pig sector. In the UK, the VMD is encouraging the livestock sectors to develop systems appropriate to their own unique circumstances and industry characteristics.
Tim said: "It’s therefore in cattle farmers’ own interests to anticipate the kind of figures it might be asked to supply in the future, and develop a way of collecting that data which suits the way the UK industry works.
"Then we can retain control over the data and the methodology, and ensure the reporting is accurate – and this in turn will help the VMD represent our case better in Europe as this debate continues.
CHAWG says that throughout this project, it will be liaising with others – such as the pig sector – to ensure learnings are shared, duplication avoided and efficiencies realised where possible.
The CHAWG review report is available to download at www.chawg.org.uk.
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
1,219 farmers took part in the survey: 44% beef and 56% dairy. For the first time, the survey was also tailored for the regions. 488 responses came from famers in England, 380 from Scotland, 164 from Wales and 237 from Northern Ireland.
Boehringer Ingelheim’s Matt Yarnall, who led the project, said: "Headline findings are that farmers have regrets about holding onto persistently infected animals (PIs) which, at the end of the day, no-one should be doing.
"The financial benefit of being free of BVD was estimated as being over £90 per cow per year and when asked what impact BVD has had on their herd, the majority of producers highlighted poor fertility and high levels of disease in the herd.”
Boehringer says the identification of persistently infected animals (PIs) through tag and testing, supported by improved herd biosecurity and vaccination, could cost as little as £10 per cow per year, representing a significant return on investment for a disease with severe financial impact.
Matt said: "Herd biosecurity is also hugely variable. The most commonly selected response was operating a closed herd but, as most practitioners will know, the definition of a true closed herd and the real-life execution of that can be two very different things."
Highlighting one of the other major challenges for producers in cattle-dense areas, results from Scotland that showed that 51% of farmers with neighbouring cattle are worried about their neighbours' BVD status.
Matt said: "Perhaps the most alarming finding was the lack of awareness of the intricacies of some BVD vaccination courses, especially around when they need to be restarted, in order to achieve the protection needed."
2017 survey data from last year showed that 71% of producers were failing to achieve adequate protection when using a BVD vaccine that requires a booster six months after the primary course.
Boehringer says the results showed this is mostly down to not properly understanding the exact nature of the timings for the two-dose primary course, dates of service and calving and then the booster date.
Matt added: "For any practitioner advising clients, the 2018 finding that a shocking 85% haven’t restarted a vaccination course when the majority should have done, should ideally serve as a clear call to action."
For more information about the findings of the National BVD Survey, email bvdzero.uk@boehringer-ingelheim.com.
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
US-based Life Technologies has launched a new PCR-based test system which, according to the company, allows large numbers of pigs to be screened more quickly and cost-effectively for a range of common pathogens, such as PRRSV, SIV and PCV2.
The system uses samples of oral fluids which can be obtained by leaving a cotton rope in each pen for pigs to chew on. After 20 minutes or so, the rope can be retrieved and the saliva and gingival crevicular fluid squeezed into a sample bag and represents a pooled sample from the group.
Studies have demonstrated that oral fluid samples collected in this way can form the basis of a quick and cost-effective method for screening a range of common viral pathogens. The samples were tested using a commercially available sample preparation and real-time PCR test system which can isolate and identify viral nucleic acid in a matter of hours.
For PRRS, pooled samples of oral fluids were collected from groups of experimentally infected pigs using the rope technique, along with serum samples from each individual pig on the same days. Both serum samples and oral fluids were processed using the same Applied Biosystems preparation system and real- time PCR test, both of which were supplied by Life Technologies. The results showed that PRRSV nucleic acid was detectable in both serum and oral fluid samples from the day of infection through to 40 days after infection.
For PCV2, 24 pigs that were free of PRRSV and SIV were divided into 4 pens in separate rooms, and challenged with two different virus strains (PCV2a and PVC2b) at different times. One pen acted as a (non-challenged) control. Oral fluids were collected regularly up to 140 days after initial challenge and tested using real-time PCR. High titres of PCV2 were detected from day 12 to day 28 post infection and virus was detectable throughout the entire testing period (days 2 to 98).
For SIV, a total of 180 spiked oral fluid samples were tested using real-time PCR, and subtyping reagents were also used to identify haemagglutinin and neuraminidase subtypes. The results showed that SIV nucleic acid was detectable in oral fluid samples spiked with high, medium and low copy numbers of SIV, and all positive samples could be successfully sub-typed.
Christina Boss, European Professional Service Veterinarian for Life Technologies said: "Collecting samples in this way is far less invasive for the pigs and so avoids unnecessary stress. And because all of the pigs will chew on the rope, it provides a very broad sample from the group, which is the key to assessing overall herd health. In addition, if the pooled sample provides a positive result, then the animals in that pen can be tested individually to identify those that are infected.
"These results show that the simplicity of oral fluid sampling, combined with the speed and sensitivity of a PCR-based system, provides a practical and cost- effective way of monitoring large numbers of pigs for common virus pathogens.
"The use of a semi-automated, PCR-based diagnostic system means that nucleic acid purification can be achieved in just 25 minutes and results from the real-time PCR available in 90 minutes. The molecular test is very specific and reliable, so the veterinarian can initiate individual testing as quickly as possible and make confident recommendations to the producer."
According to Life Technologies, screening for PRRS using samples of oral fluids has been gaining popularity over recent years because large numbers of pigs can be tested without increased cost or labour. The new research is due to be presented as a poster at the ESPHM meeting in Bruges in April.
The role was created last November when the Animal & Plant Health Agency (APHA) started allowing para-professional staff to support vets in carrying out TB testing in England.
UK Farmcare says there are now 49 fully authorised ATTs in England with another 21 TB testing under veterinary supervision and three undergoing the theory part of the training.
To become an ATT, applicants must be at least 18 years old, hold a valid UK driving licence and passport, possess a clean criminal record and then be approved by the APHA. Applicants also need at least three graded GCSEs or equivalent in English, Maths and a science or food production subject and at least six months cattle handling experience.
https://ukfarmcare.com/an-introduction-to-the-att-role.
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
CEVA Animal Health has announced that its live enzootic abortion vaccine, CEVAC® Chlamydophila, now has an added benefit. It can be used simultaneously with the only available toxoplasmosis vaccine. According to CEVA, infectious abortion, particularly enzootic abortion (Chlamydiosis), has been known to wipe out up to 50% of lambs. Strategic use of CEVAC® Chlamydophila, a live enzootic abortion vaccine, can not only prevent abortion but can also control excretion and the threat of infection.
The company says: "CEVAC® Chlamydophila makes practical and economic sense. A vaccination every four years will help your clients’ flocks remain chlamydiosis-free and the cost of treatment should work out at well under 75p per sheep per year. This is a tiny investment for your clients, to prevent the financial loss of an abortion. The fact that the product can now be used on the same day as the toxoplasmosis vaccine means that is now one of the most convenient and affordable methods currently available."
Ideally routine preventative measures should be taken prior to mating and when new sheep are introduced to the flock, to ensure abortion and infection rates always remain as low as possible.
All animals should be vaccinated in the first year, with replacements being vaccinated from six months of age, at least four weeks prior to tupping.
CEVAC® Chlamydophila is quick and easy to administer, using the special, multi-dose injector gun. One bottle of vaccine contains enough for 20 doses.
For further product information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or visit the website at http://www.ceva.uk.com/
The new Flock Health Checklist is designed to helps practitioners assess performance across the three crucial time periods and two key management processes which have an impact on the success of sheep enterprises.
Dr Kat Baxter-Smith, veterinary adviser with MSD Animal Health said: “We have developed this new performance checklist drawing on specialist sheep vet working experiences, clinical research studies, economic data and industry recommendations.
"For example, the pre-breeding period is a great time to make sure ewes and rams are as fit and healthy as possible.
"Good practice and preparation in this area will go a long way to minimising stress and problems during a busy lambing period.”
Late pregnancy and lambing period is also a vital time – and is the busiest few weeks on any sheep farm.
Kat added: “Having pre-agreed protocols for this important period in the sheep farming calendar – and keeping a record of issues that arise – will go a long way to making sure subsequent lambing seasons go as smoothly as possible.”
Growth, weaning and sale is the third crucial time period and the Flock Health Checklist incorporates an additional series of audit-based questions designed to pinpoint system strengths and weaknesses.
The Flock Health Checklist also enables vets to ask a series of questions covering two key management processes: disease management and biosecurity; and how flock performance is currently monitored.
Kat said: “Working through a series of 10 questions within each of the three crucial time periods and two key management processes – designed to tease out where a sheep unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to montor performance against agreed targets.
“Similar types of checklist have been available to dairy youngstock rearing units and beef suckler herds for a couple of years now, with several vets reporting that these tools have proved integral to their productivity improvement work with farmer clients.
"Use of this checklist-based approach is also helping better implementation of preventative health practices such as vaccination. We hope this latest tool will help the GB sheep industry similarly.”
For further information, contact your local MSD Animal Health account manager.
Bimeda has launched Recocam, a 20mg/ml meloxicam preparation licensed for use as a single injection course in cattle, horses and pigs.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "Meloxicam's anti-inflammatory credentials and safety profile is well proven and it remains rightly popular with large animal vets. With our manufacturing expertise it makes sense to add this widely used product to our portfolio. Our aim is to provide a comprehensive range of both established standards and new innovative products for cattle and equine vets, and this is just another step in that process."
Bimeda says Recocam has a broad range of indications including acute respiratory infections, in combination with oral re-hydration in diarrhoea therapy and acute mastitis, for non-infectious locomotor disorders and lameness in pigs and alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and pain relief associated with equine colic. In cattle Recocam can be given by single subcutaneous or intravenous injection.
Grahame Gardner Ltd has announced the launch of a classically styled tunic, the M559, now stocked in bottle green for the first time.
The company says that although there have been numerous ladies tunics available in bottle green, this is the first time Grahame Gardner has stocked a male tunic in the characteristic veterinary colour.
The contemporary design of the M559 incorporates side fastening with the option of contrasting epaulettes, alongside practical pockets and side slits. According to the company, it's a tunic that looks great and performs exceptionally well in the veterinary practice. Stocked in sizes from 34" to 50" (chest), the M559 is one of several new styles introduced within Grahame Gardner's latest 124 page brochure.
To explore Grahame Gardner's collection please take a look at http://www.grahamegardner.co.uk/, or call 0116 255 6326 to order a copy of the new brochure.
Cyclofin contains two active ingredients: 200 mg/ml of the anti-inflammatory flunixin-meglumine (eq. to 33.2 mg/ml flunixin meglumine) and 300 mg/ml of the class D anti-infective, oxytetracycline (eq. to 323.5 mg/ml oxytetracycline trihydrate).
Dechra says Cylofin acts within 24-36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.
Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1 ml per 10 kg body weight.
Alana McGlade MRCVS, national sales manager at Dechra, said: “BRD is one of the most prevalent and costly diseases on farm and early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”
Cyclofin is available in 100ml vials.
https://www.dechra.co.uk/products/livestock/prescription/cyclofin#Cyclofin-300mg-ml.
Two winners will be flown from a London airport to spend 2 nights at the Krka Terme Hotel Svoboda Strunjan, a night at the Grand Union Hotel Ljubljana and a night at the Grand Hotel Bled, plus car hire.
To enter, visit www.discoverkrka.co.uk and pick out the differences between the Dalmations.
Ned Flaxman from Krka said: "I’ve only recently joined KRKA and I’m sure like many people I imagined Slovenia to be some far-off country in Eastern Europe. But it’s much closer than you might think - being only a couple hour’s boat ride from Venice.
"I would urge anyone to enter the competition to be in with the chance of winning this truly memorable trip. From the cliffs and stunning beaches of Strunjan to the lively and beautiful city of Ljubljana, Slovenia is a hidden gem just waiting to be discovered."